The systemic effectiveness of KY19334 on the anti-obesity was acquired by blockade of the function of the aberrantly overexpressed CXXC5 and subsequent inhibition of the Wnt/β-catenin signaling suppression in the early developmental stage of obesity by HFD. The gene discussed is CXXC5; the disease is obesity disorder.